Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 11;9(3):e002087. doi: 10.1136/jitc-2020-002087

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Change in standard parental immune cell types and refined subsets after corticosteroids. Cancer patients (n=11) enrolled in immunotherapy trials received moderate- to high-dose corticosteroids (prednisone, n=6; methylprednisolone and prednisone, (n=4); or dexamethasone, methylprednisolone, and prednisone, n=1) for the development of immune-related adverse events. (A–F) Changes in standard parental immune cell types after corticosteroids. (G–J) Representative graphs are shown for notable refined subsets that changed with corticosteroids. Significant changes were defined by a p value <0.05, a median difference poststeroid versus presteroids >0.05% of PBMCs, and at least half of evaluated patients having a >25% change. The panels used for refined subsets reflecting maturation/functional status of subsets were slightly different for the various immunotherapy trials, so certain subsets were not tested in all patients (n=6 for Treg CD38 and non-classical monocytes). MDSCs, myeloid-derived suppressor cells; PBMCs, peripheral blood mononuclear cells; Tregs, regulatory T cells.